Contineum Therapeutics welcomes Troy Ignelzi to its Board as Independent Director

– USA, CA –  Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical-stage biopharmaceutical company, today announced the appointment of Troy Ignelzi to its Board as an Independent Director, bringing nearly two decades of financial leadership and industry experience to the board.

Troy Ignelzi will also join the Audit Committee as Chair.

“I am extremely pleased to welcome Troy to the Contineum board. Troy’s recent public markets experience, coupled with his proven track record in building and financing precision neuroscience companies, will be invaluable to us as we seek to advance our pipeline of NI&I therapies toward patients in need,” said CEO Carmine Stengone.

About Troy Ignelzi

Troy Ignelzi serves as CFO at Rapport Therapeutics, Inc., a precision neuro medicines company, where he has served since November 2023. Before that, he was CFO at Karuna Therapeutics, Inc., a neurological disease company. He led the team in executing a private crossover round, the company’s IPO, and multiple follow-on financings. Before Karuna, Troy Ignelzi served as CFO at Juventas Therapeutics and scPharmaceuticals.

He began his career at Eli Lilly and then held roles of increasing responsibility at several biotechnology companies including Esperion Therapeutics, Inc. and Insys Therapeutics, Inc. Previously, he served on the board of CinCor Pharma, Inc., where he advised on the company’s sale to AstraZeneca in early 2023. He serves on the boards of Vedanta Biosciences and Abivax and is an Executive Advisor for Sofinnova Investments. Mr. Ignelzi is a graduate of Ferris State University, where he earned his B.S. in accounting.

“The approach that Contineum has spearheaded in the NI&I space is truly unique. Their vision of developing oral small molecules that target proven biological pathways like LPA1 and M1 has the potential to change the lives of many people living with serious fibrotic or neurological disorders such as idiopathic pulmonary fibrosis and depression,” said Troy Ignelzi. “I am excited to bring my experience with neuroscience companies to the Contineum board and help guide the company’s financial strategy and growth.”

About Contineum Therapeutics

Contineum Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel, oral small-molecule therapies for NI&I indications with high unmet needs. Contineum is focused on targeting biological pathways associated with specific clinical impairments, that Contineum believes, once modulated, may demonstrably impact the course of the disease. Contineum has a pipeline of internally developed programs to address multiple NI&I disorders. PIPE-791 is an LPA1 receptor antagonist which recently completed a Phase 1 healthy volunteer clinical trial to support ongoing clinical development for idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). PIPE-307, a selective inhibitor of the M1 receptor, is currently in a Phase 2 clinical trial for relapse remitting MS, and a Phase 2 trial in depression is planned to be initiated in 2024. Contineum is developing PIPE-307 in collaboration with Johnson & Johnson Innovative Medicines.


- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.